Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.53 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
| ▸ | TUBB | P07437 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764660 | 0.88 | KDM4E (0.56) | KDM4ECYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL775093 | 0.85 | MGAM (0.53) | KDM4ECYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL16894621 | 0.83 | ABCG2 (0.73) | KDM4ECYP3A4ABCG2ADORA3ABCB1 | |
| SCHEMBL571690 | 0.82 | MAOA (0.48) | KDM4ECYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL380907 | 0.80 | ADORA3 (0.73) | KDM4ECYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL16894634 | 0.78 | ABCB1 (0.51) | KDM4ECYP3A4ABCG2ADORA3ABCB1 | |
| SCHEMBL25065758 | 0.76 | MEN1 (0.70) | KDM4EHSD17B10ABCG2ABCB1MEN1 | |
| SCHEMBL17237780 | 0.75 | MAOA (0.59) | KDM4ECYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL31182979 | 0.75 | ABCG2 (0.55) | KDM4ECYP3A4CYP2C9HSD17B10ABCG2 | |
| SCHEMBL774317 | 0.74 | ADORA3 (0.72) | KDM4ECYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118091005-A | Method for detecting multiple components in deer astragalus kidney-tonifying particles | 上海市第七人民医院(上海中医药大学附属第七人民医院) | 2024-05-28 | — | — | CN | claimed |
| CN-109374762-B | Method for identifying citrus reticulata blanco and citrus reticulata blanco varieties based on metabonomics | 广州中医药大学第一附属医院 | 2021-10-08 | — | — | CN | claimed |
| US-20100178390-A1 | Micronutrient-Simulated Beverages | THE COCA-COLA COMPANY (US) | 2010-07-15 | — | — | US | claimed |
| WO-2010080866-A2 | MICRONUTRIENT-SIMULATING BEVERAGES | THE COCA-COLA COMPANY (US) | 2010-07-15 | — | — | WO | claimed |
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | DEEPSENSE BIOTECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260118258-A1 | VALIDATION OF NATURAL MATRICES FOR THERAPEUTIC USE | BIOS THERAPY PHYSIOLOGICAL SYSTEMS FOR HEALTH S P A (IT) | 2026-04-30 | — | — | US | disclosed |
| US-12546707-B2 | Validation of natural matrices for therapeutic use | Bios-Therapy, PhysiologicalSystems for Health S.p.A. (IT) | 2026-02-10 | — | — | US | disclosed |
| US-20250383340-A1 | METHODS FOR DETERMINING WHEN A NATURAL THERAPEUTIC OR BENEFICIAL PRODUCT EXERTS ITS THERAPEUTIC OR BENEFICIAL EFFECT THROUGH A PHYSIOLOGICAL MODE OF ACTION | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-12-18 | — | — | US | disclosed |
| US-20250383343-A1 | METHODS FOR DETERMINING WHEN A NATURAL THERAPEUTIC OR BENEFICIAL PRODUCT EXERTS ITS THERAPEUTIC OR BENEFICIAL EFFECT THROUGH A PHYSIOLOGICAL MODE OF ACTION | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-12-18 | — | — | US | disclosed |
| US-20250231101-A1 | VALIDATION OF NATURAL MATRICES FOR THERAPEUTIC USE ON HUMANS, ANIMALS AND PLANTS ON BIO-PHYSICAL BASES AS AN ALTERNATIVE TO VALIDATION THROUGH CHEMICALLY DEFINABLE SUBSTANCES DERIVED FROM SAID MATRICES BY ISOLATION AND/OR SYNTHESIS PROCESSES AND ALSO AS AN ALTERNATIVE TO PRODUCTS COMPRISING NATURAL MATRICES VALIDATED ON THE BASIS OF THEIR TRADITIONAL USE | BIOS-THERAPY, PHYSIOLOGICAL SYSTEMS FOR HEALTH S.P.A. (IT) | 2025-07-17 | — | — | US | disclosed |
| CN-120009445-A | Detection method and kit for ageing process | 中国检验检疫科学研究院 | 2025-05-16 | — | — | CN | disclosed |
| EP-4493725-A1 | METHODS FOR STRATIFICATION OF PARKINSON'S DISEASE PATIENTS, SYSTEMS AND USES THEREOF | Université du Luxembourg (LU) | 2025-01-22 | — | — | EP | disclosed |
| WO-2007024982-A2 | METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION | WELLGEN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070042972-A1 | Compositions and methods for optimizing exercise recovery | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2007-02-22 | — | — | US | disclosed |
| WO-2006127996-A2 | COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-6987125-B1 | Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2006-01-17 | — | — | US | disclosed |
| US-20050226828-A1 | Method for whitening human skin | NOF CORPORATION | 2005-10-13 | — | — | US | disclosed |
| EP-1119353-A4 | COMPOSITIONS AND METHODS OF INHIBITING NEOPLASTIC DISEASES WITH COMPOUNDS RELATED TO LIMOCITRIN AND 5-DESMETHYL SINENSETIN | KGK SYNERGIZE INC (CA) | 2002-08-28 | — | — | EP | disclosed |
| EP-1119353-A1 | COMPOSITIONS AND METHODS OF INHIBITING NEOPLASTIC DISEASES WITH COMPOUNDS RELATED TO LIMOCITRIN AND 5-DESMETHYL SINENSETIN | KGK Synergize Inc. (CA) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000019998-A1 | COMPOSITIONS AND METHODS OF INHIBITING NEOPLASTIC DISEASES WITH COMPOUNDS RELATED TO LIMOCITRIN AND 5-DESMETHYL SINENSETIN | KGK SYNERGIZE (CA) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042972-A1 | Compositions and methods for optimizing exercise recovery | GYS1, PYGM, PRDX5 | KDM4E 121/4885CYP3A4 144/4885CYP2C9 93/4885 |
| US-20050226828-A1 | Method for whitening human skin | CUTA, POLN, PLIN5 | KDM4E 454/4885CYP3A4 2403/4885CYP2C9 1637/4885 |
| US-12546707-B2 | Validation of natural matrices for therapeutic use | COL2A1, IL1B, COL1A1 | KDM4E 2599/4885CYP3A4 2885/4885CYP2C9 2064/4885 |
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | PLIN3, PNLIP, FABP2 | KDM4E 2460/4885CYP3A4 39/4885CYP2C9 178/4885 |
| US-20260118258-A1 | VALIDATION OF NATURAL MATRICES FOR THERAPEUTIC USE | SOST, FABP4, COL2A1 | KDM4E 1247/4885CYP3A4 2659/4885CYP2C9 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.